Navigation Links
Kewaunee Scientific Reports Improved Results for Third Quarter
Date:2/26/2013

STATESVILLE, N.C., Feb. 26, 2013 /PRNewswire/ -- Kewaunee Scientific Corporation (Nasdaq: KEQU) today reported sales and earnings for its third quarter ended January 31, 2013.

Sales for the quarter were $27,450,000, up 27% from sales of $21,574,000 in the third quarter last year. Net earnings for the quarter were $544,000, or $0.21 per diluted share, as compared to a net loss of $122,000, or $0.05 per diluted share, in the third quarter last year. Earnings for the quarter were favorably impacted by the increase in sales, continued strong results from International operations, and reduced manufacturing, overhead, and administrative costs. The order backlog was $84.5 million at January 31, 2013, up from $77.1 million at January 31, 2012.

Domestic sales for the quarter were $20,445,000, up 19% from sales of $17,142,000 in the third quarter last year. The Company continues to make excellent progress in winning projects through its strengthened dealer network. The marketplace for privately-funded projects continued to hold up relatively well during the quarter, while opportunities for publicly-funded wood educational projects remained well below pre-recession levels, as state and local governments continued to receive significantly lower funding for capital projects.

International sales for the quarter were $7,005,000, up 58% from sales of $4,432,000 in the third quarter last year. The Company has a strong backlog of international orders and continues to see increased opportunities for sales and orders in the growing Asia and Middle East laboratory markets.

Sales for the nine months ended January 31, 2013 were $85,318,000, up 16% over sales of $73,857,000, in the comparable period last year.  Domestic sales were $68,757,000, up 7% over sales of $64,364,000 in the same period last year.  International sales were $16,561,000, up 74% from sales of $9,493,000 in the same period last year. Net earnings for the nine months ended January 31, 2013 were $1,827,000, or $0.71 per diluted share, as compared to a net loss of $225,000, or $0.09 per diluted share, in the comparable period last year.

The Company's balance sheet continues to be strong. Cash on hand was $4.9 million at the end of the quarter, as compared to $4.6 million at January 31, 2012.  Working capital was $24.3 million, as compared to $21.5 million at the end of the same period last year. Short-term borrowings under the Company's $15 million bank line of credit were $2.7 million, as compared to $6.4 million at January 31, 2012. Total bank borrowings and capital lease obligations were $6.2 million, as compared to $10.2 million at the end of the third quarter last year, and the debt-to-equity ratio was .20-to-1, as compared to .34-to-1.

"We continued to make excellent progress during the quarter," said William A. Shumaker, Kewaunee's Chief Executive Officer. "I am pleased with sales and earnings, particularly since the third quarter is historically our slowest due to normal construction cycles and the large number of holidays. We continue to see positive results from our strengthened domestic dealer network and our broadened international dealer network. When combined with our lower manufacturing costs, this is providing us with more opportunities to close orders in both of these geographic markets.

"Looking forward, we expect to have a strong finish to our year. Incoming orders and customer delivery requirements for our metal furniture, fume hoods, and epoxy resin products have provided us a strong backlog of orders scheduled to ship in the fourth quarter. This increased demand and our lower costs are expected to more than offset the continuing lower demand for publicly-funded wood educational projects. It should be mentioned that results for the fourth quarter of last year were unusually strong, as results were favorably impacted by several large international projects that were manufactured and shipped during the quarter."

Kewaunee Scientific Corporation is a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. Laboratory furniture products include both steel and wood cabinetry, fume hoods, adaptable modular systems, moveable workstations, biological safety cabinets, and epoxy resin counters and sinks. Healthcare furniture products include laminate casework, storage systems, and related products for healthcare applications. Technical furniture products include column systems, slotted-post systems, pedestal systems, and stand-alone benches.

The Company's corporate headquarters are located in Statesville, North Carolina. Three manufacturing facilities are located in Statesville, NC serving the domestic and international markets. One manufacturing facility is located in Bangalore, India serving the local and Asian markets. The Company has subsidiaries in Singapore and India. Kewaunee Scientific's website is located at http://www.kewaunee.com.

Certain statements in this release constitute "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. These factors include, but are not limited to, economic, competitive, governmental, and technological factors affecting the Company's operations, markets, products, services, and prices.

 Kewaunee Scientific CorporationConsolidated Statements of Operations (Unaudited)(in thousands, except per share data)Three months endedNine months ended January 31, January 31,2013201220132012Net sales$
27,450$
21,574$
85,318$
73,857Cost of products sold22,44117,80369,83962,053Gross profit5,0093,77115,47911,804Operating expenses4,0543,99012,20511,950Operating earnings (loss)955(219)3,274(146)Other income84193260228Interest expense(80)(110)(295)(333)Earnings (loss) before income taxes959(136)3,239(251)Income tax expense (benefit)177(170)962(237)Net earnings (loss)782342,277(14)Less: net earnings attributable tothe noncontrolling interest238156450211Net earnings (loss) attributable to Kewaunee Scientific Corporation$
544$
(122)$
,827$
(225)Net earnings (loss) per share attributable toKewaunee Scientific Corporation stockholdersBasic$
.21$
(0.05)$
.71$
(0.09)Diluted$
.21$
(0.05)$
.71$
(0.09)Weighted average number of common  shares outstandingBasic2,5902,5792,5862,579Diluted2,6042,5792,5962,579 Kewaunee Scientific CorporationCondensed Consolidated Balance Sheets(in thousands)January 31,April 30,20132012Assets(Unaudited)Cash and cash equivalents$
4,202$
,188Restricted Cash692704Receivables, less allowances20,06423,244Inventories12,88811,760Prepaid expenses and other current assets2,2691,702Total Current Assets40,11543,598Net property, plant and equipment14,89015,346Other assets5,6185,192Total Assets$
,623$
4,136Liabilities and EquityShort-term borrowings$
2,707$
,816Current obligations under capital leases and long-term debt200236Accounts payable8,5628,848Other current liabilities4,3604,340Total Current Liabilities15,82920,240Other non-current liabilities12,09512,238Total Liabilities27,92432,478Noncontrolling interest1,8452,147Kewaunee Scientific Corporation equity30,85429,511Total Equity32,69931,658Total Liabilities and Equity$
,623$
4,136 

Contact:

D. Michael Parker704/871-3290 


'/>"/>
SOURCE Kewaunee Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
2. Kewaunee Scientific Corporation Declares Quarterly Dividend
3. Kewaunee Scientific Reports Record Sales for Second Quarter
4. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
5. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
6. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
7. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
8. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
9. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
10. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
11. Generex Augments Antigen Express Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... INDIANAPOLIS , Feb. 12, 2016  Eli Lilly and ... High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent ... in the UK, France , ... instructions to dilute the product only with dextrose solution.  ... of 2015, the UK Court of Appeal held that Lilly,s ...
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
Breaking Medicine Technology:
(Date:2/12/2016)... Omaha, NE (PRWEB) , ... February 12, 2016 , ... ... list of the five most searched jobs via the website of healthcare staffing leader ... professionals in travel nurse jobs , travel therapy positions and in ...
(Date:2/12/2016)... ... February 12, 2016 , ... The aging population and ... long term care. With that, says Patrick Loughney, president of Longtree & ... in long term care environments. His company, which offers prep courses and workshops ...
(Date:2/12/2016)... ... 12, 2016 , ... Basketball is a game for everyone, not just those ... series, sign language translation is featured in the top right of the screen. Every ... lessons has a sign language translator to teach kids the game and how to ...
(Date:2/12/2016)... ... February 12, 2016 , ... With the exception of restorative dentistry, to date there has been ... the recent approval by the FDA, there is a now a new protocol in stopping ... is very simple and quick to apply. The application is as simple as drying ...
(Date:2/11/2016)... ... ... Fitbody Personal Training offers outdoor training classes which includes an equestrian boot ... healthy. Located in Phoenixville, PA, the classes are structured as fun and friendly. , ... want to lose weight and tone up. This class offers a balance of exercises ...
Breaking Medicine News(10 mins):